department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Imfinzi · pharmadog

pharmadog
drugs
Imfinzi

drug · antibody

patient view →

durvalumab

pre_registrationupdated 2mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 67 investigational indications.

indications

indications

NSCLC

targets

Programmed cell death 1 ligand 1

all catalysts(2)

phase 2 initiation · 1

phase 3 completion · 1

News(0)

no news has mentioned this drug yet

brand

Imfinzi

trade names

Imfinzi

generic

durvalumab

MOA

Programmed cell death 1 ligand 1 inhibitor

indication

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

phase

pre_registration

phase 2 initiation

Jazz Pharmaceuticals Plc — durvalumab (Phase II Trial Initiation)

phase 3 completion

AstraZeneca Plc — durvalumab (Phase III Trial Completion)

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 57m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$JAZZ244.17+0.29%

$AZN190.16-2.56%

🐶 often sniffed alongside

top 7

tagApproval104 co-mentions · 26 sources
tagOncology11 co-mentions · 2 sources
tagNephrology3 co-mentions · 1 sources
company$AZNASTRAZENECA PLC1 co-mentions · 1 sources
company$JAZZJazz Pharmaceuticals plc1 co-mentions · 1 sources
tagPulmonology1 co-mentions · 1 sources
tagNSCLC1 co-mentions · 1 sources

Trials studying durvalumab

phase2Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)active not recruitingn=142
phase3A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Canceractive not recruitingn=1,051
phase3A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)recruitingn=1,100
phase2A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studiesrecruitingn=60
phase2A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapyactive not recruitingn=39
phase3Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.recruitingn=70
phase2Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trialactive not recruitingn=63
phase3A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCrecruitingn=860

more trials →